Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript

Core Points - Kamada has announced the discontinuation of its Phase III inhaled AAT InnovAATe clinical trial [3] - The company provided an update on its financial projections during the corporate update call [3] Company Update - The decision to discontinue the clinical trial was communicated in a press release issued earlier [3] - The corporate update call included participation from Kamada's CEO Amir London and CFO Chaime Orlev [2] Financial Projections - The financial projections discussed in the call are a key focus for the company moving forward [3]